SteadySharesSteadyShares
The market
MarketsDiscover
Follow the money
Smart MoneyPolitician TradesCrypto Desk
Yours
My WealthNews
Settings Sign in to save your work
After hours
SteadySharesMarketsDiscoverSmart MoneyMy WealthPoliticiansCryptoNews
/
DiscoverAZN
HealthcareNASDAQUSD

AstraZeneca (ADR)

$001234567890012345678900123456789.0012345678900123456789-5.3%
52w low (est.) $140.30$208.44 52w high (est.)
Peers
Market data
Market cap
$266.15B
52-week range
$137.22 – $212.71
Beta (vs market)
0.23
Sector
Healthcare
Valuation
P/E ratio
25.8x
DCF fair value
$109.23
Margin of safety
-35.5%
Forward P/E
18.5x
PEG ratio
1.44
Dividend yield
1.84%
Quality & efficiency
Moat score
84/100
Return on equity
23.5%
Profit margin
17.2%
Debt / equity
0.72
Growth & analysts
Revenue growth (YoY)
+12.5%
Analyst target
$221.09
Target upside
+30.6%
Analysts covering
10

About AstraZeneca (ADR)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Valuation

ValueGrowthProfitHealthIncome46QUALITY
Overall Rating
49
Hold
Hold
Moat Score84
DCF Intrinsic Value
$109.23-35.5% downside

Moat, DCF and rating computed by our valuation engine (ported from the original Python model).

Fundamentals

Market Cap
$266.15B
P/E Ratio
25.8
Dividend Yield
1.84%
Revenue Growth
+12.5%
Profit Margin
17.2%
ROE
23.5%
Debt / Equity
0.72
Beta
0.23
vs Healthcare sector:P/E 26 vs 28 · cheaperMoat 84 vs 7Yield 1.84% vs 0.3%

Statistics

Similar Stocks · Healthcare

LLY73
$920.00+0.7%
AZN.L72
£105.20+0.6%
UNH71
$492.10+1.6%
JNJ70
$146.20-0.2%

Latest News · AZN